Prognosis
Novavax Covid-19 Vaccine Gets Fast-Track Tag From FDA
- Shares build on gains as company readies late-stage trial
- Company has received $1.6 billion from Operation Warp Speed
Photographer: Andrew Caballero-Reynolds/AFP/Getty Images
This article is for subscribers only.
Sign up here for our daily coronavirus newsletter on what you need to know, and subscribe to our Covid-19 podcast for the latest news and analysis.
Novavax Inc.’s experimental Covid-19 vaccine received a fast-track designation from U.S. regulators as the drugmaker prepares to launch a large, late-stage study before the end of the month, the company said on Monday.